149 related articles for article (PubMed ID: 23444076)
1. Increased expression of survivin in hepatoblastoma after chemotherapy.
Uehara S; Oue T; Kawatsu M; Nara K; Fukuzawa M
Eur J Pediatr Surg; 2013 Oct; 23(5):400-4. PubMed ID: 23444076
[TBL] [Abstract][Full Text] [Related]
2. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
Häberle B; Bode U; von Schweinitz D
Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
[TBL] [Abstract][Full Text] [Related]
4. Analysis of treatment efficiency of carboplatin and etoposide in combination with radical surgery in advanced and recurrent childhood hepatoblastoma: a report of the German Cooperative Pediatric Liver Tumor Study HB 89 and HB 94.
Fuchs J; Bode U; von Schweinitz D; Weinel P; Erttmann R; Harms D; Mildenberger H
Klin Padiatr; 1999; 211(4):305-9. PubMed ID: 10472567
[TBL] [Abstract][Full Text] [Related]
5. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737.
Lieber J; Dewerth A; Wenz J; Kirchner B; Eicher C; Warmann SW; Fuchs J; Armeanu-Ebinger S
Oncol Rep; 2013 Feb; 29(2):646-52. PubMed ID: 23229825
[TBL] [Abstract][Full Text] [Related]
6. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group.
Schnater JM; Aronson DC; Plaschkes J; Perilongo G; Brown J; Otte JB; Brugieres L; Czauderna P; MacKinlay G; Vos A
Cancer; 2002 Feb; 94(4):1111-20. PubMed ID: 11920482
[TBL] [Abstract][Full Text] [Related]
7. The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model.
Warmann S; Hunger M; Teichmann B; Flemming P; Gratz KF; Fuchs J
Cancer; 2002 Oct; 95(8):1795-801. PubMed ID: 12365029
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma.
Perilongo G; Maibach R; Shafford E; Brugieres L; Brock P; Morland B; de Camargo B; Zsiros J; Roebuck D; Zimmermann A; Aronson D; Childs M; Widing E; Laithier V; Plaschkes J; Pritchard J; Scopinaro M; MacKinlay G; Czauderna P
N Engl J Med; 2009 Oct; 361(17):1662-70. PubMed ID: 19846851
[TBL] [Abstract][Full Text] [Related]
9. Survival after liver transplantation for hepatoblastoma: a 2-center experience.
Browne M; Sher D; Grant D; Deluca E; Alonso E; Whitington PF; Superina RA
J Pediatr Surg; 2008 Nov; 43(11):1973-81. PubMed ID: 18970927
[TBL] [Abstract][Full Text] [Related]
10. Effects of neoadjuvant chemotherapy on hepatoblastoma: a morphologic and immunohistochemical study.
Wang LL; Filippi RZ; Zurakowski D; Archibald T; Vargas SO; Voss SD; Shamberger RC; Davies K; Kozakewich H; Perez-Atayde AR
Am J Surg Pathol; 2010 Mar; 34(3):287-99. PubMed ID: 20118773
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor-4 agonist inhibits motility and invasion of hepatoblastoma HepG2 cells in vitro.
Hsiao CC; Kao YH; Huang SC; Chuang JH
Pediatr Blood Cancer; 2013 Feb; 60(2):248-53. PubMed ID: 22648929
[TBL] [Abstract][Full Text] [Related]
12. Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated into mice following treatment with adriamycin or cisplatin.
Bader P; Fuchs J; Wenderoth M; von Schweinitz D; Niethammer D; Beck JF
Anticancer Res; 1998; 18(4C):3127-32. PubMed ID: 9713521
[TBL] [Abstract][Full Text] [Related]
13. The influence of preoperative chemotherapy and surgical technique in the treatment of hepatoblastoma--a report from the German Cooperative Liver Tumour Studies HB 89 and HB 94.
Fuchs J; Rydzynski J; Hecker H; Mildenberger H; Bürger D; Harms D; V Schweinitz D;
Eur J Pediatr Surg; 2002 Aug; 12(4):255-61. PubMed ID: 12369004
[TBL] [Abstract][Full Text] [Related]
14. Effects of P-glycoprotein modulation on the chemotherapy of xenotransplanted human hepatoblastoma.
Warmann SW; Heitmann H; Teichmann B; Gratz KF; Ruck P; Hunger M; Fuchs J
Pediatr Hematol Oncol; 2005; 22(5):373-86. PubMed ID: 16020127
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Hokita S; Xi H; Higashi H; Baldus SE; Metzger R; Brabender J; Bollschweiler E; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
Oncol Rep; 2005 Jun; 13(6):1241-6. PubMed ID: 15870949
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study.
Zsíros J; Maibach R; Shafford E; Brugieres L; Brock P; Czauderna P; Roebuck D; Childs M; Zimmermann A; Laithier V; Otte JB; de Camargo B; MacKinlay G; Scopinaro M; Aronson D; Plaschkes J; Perilongo G
J Clin Oncol; 2010 May; 28(15):2584-90. PubMed ID: 20406943
[TBL] [Abstract][Full Text] [Related]
17. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
[TBL] [Abstract][Full Text] [Related]
18. Changing treatment and outcome of children with hepatoblastoma: analysis of a single center experience over the last 20 years.
Ismail H; Broniszczak D; Kaliciński P; Dembowska-Bagińska B; Perek D; Teisseyre J; Kluge P; Kościesza A; Lembas A; Markiewicz M
J Pediatr Surg; 2012 Jul; 47(7):1331-9. PubMed ID: 22813792
[TBL] [Abstract][Full Text] [Related]
19. Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors.
Casanova M; Massimino M; Ferrari A; Spreafico F; Piva L; Coppa J; Luksch R; Cefalo G; Terenziani M; Polastri D; Bellani FF; Mazzaferro V
Pediatr Hematol Oncol; 2005; 22(3):189-98. PubMed ID: 16020101
[TBL] [Abstract][Full Text] [Related]
20. Predictive role of midtreatment changes in survivin, GSTP1, and topoisomerase 2α expressions for pathologic complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Eralp Y; Keskin S; Akışık E; Akışık E; İğci A; Müslümanoğlu M; Yılmaz S; Tunacı M; Çamlıca H; Tuzlalı S; Saip P; Dalay N; Özmen V; Topuz E
Am J Clin Oncol; 2013 Jun; 36(3):215-23. PubMed ID: 22441341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
